Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Entheon Biomedical Corp (OP: ENTBF )

0.0982 +0.0062 (+6.74%)
Streaming Delayed Price Updated: 1:53 PM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Entheon Biomedical Corp

< Previous 1 2 Next >
World Class Leaders In Psychedelics Form Benzinga's Psychedelic Advisory Council—Get To Know Them
The Benzinga Psychedelics Advisory Council was introduced in March of 2022 with the sustained goal of better informing investors and general audience about the psychedelics financial and business... 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Poised to Accelerate Its CYB004 Clinical Development Program
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Acquires DMT Study Expected to Accelerate Clinical Development Path of CYB004
Via Investor Brand Network
Psyched: Elon Musk Tweets About Psychedelics, Numinus Acquires Novamind, Colorado Gov. Signs MDMA Legalization Bill
Want to get the latest psychedelics industry news in your inbox every week? Subscribe to our Newsletter to become a Psychedelics Insider. 
Via Benzinga
Largest Phase-1 DMT Study In The Netherlands, A Collaboration Between Entheon & Cybin
Cybin Inc. (NEO:CYBN) (NYSE American: CYBE) announced that, through its wholly-owned subsidiary Cybin IRL Limited, It has entered into an agreement to acquire a Phase 1 N,N-dimethyltryptamine (“DMT”)... 
Via Benzinga
Ehave Partners With Halugen Life Sciences To Create A Ketamine Precision Medicine Platform For Clinical Research
Ehave, Inc. (OTC Pink: EHVVF) is a leading healthcare services and technology company focused on progressing psychedelics to therapeutics by engineering novel compounds and new treatment protocols for... 
Via Benzinga
Entheon Biomedical Announces Non-Brokered Private Placement Financing
Entheon Biomedical Corp. (OTCQB: ENTBF) announced anon-brokered private placement financingfor up to 30,000,000 Units at ... 
Via Benzinga
Benzinga's Unprecedented Psychedelics Investing Conference Lands In Miami On April 19th
The first Benzinga Psychedelics Capital Conference, the premier gathering of psychedelics industry leaders and forward-thinking investors, is coming to the Fontainebleau Miami Beach on April 19, 2022,... 
Via Benzinga
Psyched: Psychedelics ETF Launches On NYSE, Psilocybin Trial Approved For Depression, DMT Study Begins
This week saw new triumphs for public companies in the psychedelics space with the creation of a new ETF tracking the sector, which went public in the NYSE. 
Via Benzinga
Psychedelics Biotech Startup Launches Phase 1 Study On Ayahuasca's Active Ingredient
Psychedelics biotech startup Entheon Biomedical (CSE: ENBI) (OTCQB: ENTBF) announced the approval by the local Dutch ethics committee for a Phase 1 clinical trial evaluating the pharmacokinetics,... 
Via Benzinga
Entheon Biomedical Reports Launching Multiple Studies to Advance Psychedelic-Based Mental Health Treatments
Image provided by Flickr The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of... 
Via Benzinga
Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) Featured in Virtual Coverage of Benzinga’s Small Cap Conference
Via Investor Brand Network
Compass Pathways 2.0: A New Rally In Psychedelic Stocks?
Compass Pathways' IPO sparked a sector-wide rally in 2020. Now CMPS is on the move again. Is history about to repeat? 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Entheon Biomedical Provides Corporate Update on Studies and Clinical Trials
Vancouver, British Columbia--(Newsfile Corp. - October 27, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or... 
Via Newsfile
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
The Week In Psychedelics 
Via Benzinga
Entheon Biomedical Acquires Lobo Genetics, Inc. in Bid to Strengthen Screening and Treatment Evaluation Tech for Psychedelics
Image Provided by Wiki Commons Entheon Biomedical Corp. (OTCQB: ENTBF), the biotech research and development company focused on developing DMT-based treatments for addiction and... 
Via Benzinga
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S... 
Via Benzinga
Clinical Director of Imperial College's Center for Psychedelic Research Joins Entheon Advisory Board
Vancouver, British Columbia--(Newsfile Corp. - August 25, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or... 
Via Newsfile
Entheon Biomedical Corp. Announces DTC Eligibility
Vancouver, British Columbia--(Newsfile Corp. - August 24, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or... 
Via Newsfile
CORRECTION FROM SOURCE: BTV Examines the Rapidly Expanding Psychedelics Market
Vancouver, British Columbia--(Newsfile Corp. - August 17, 2021) - On Sun. Aug. 22nd at 5pm EST broadcast on FOX Business... 
Via Newsfile
BTV Examines the Rapidly Expanding Psychedelics Market
Vancouver, British Columbia--(Newsfile Corp. - August 17, 2021) - On Sun. Aug. 22nd at 5pm EST broadcast on FOX Business... 
Via Newsfile
Entheon Biomedical Announces Sponsorship of a Clinical Study to Assess the Electroneurophysiologic Effects of Ketamine
Vancouver, British Columbia--(Newsfile Corp. - August 12, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or... 
Via Newsfile
Exposures Product Safety
Psyched: Field Trip Uplists To Nasdaq, MindMed To Study DMT, Atai Launches New Subsidiary, AOC's Psychedelics Amendment Rejected
Last week in Psychedelics: 
Via Benzinga
Entheon Biomedical Corp. Strengthens Its Psychedelic-Assisted Protocols Through Acquisition Of Lobo Genetics
Psychedelics biotech company Entheon Biomedical Corp. (CSE:ENBI 
Via Benzinga
Entheon Biomedical Corp. Acquires Lobo Genetics Inc.
Vancouver, British Columbia--(Newsfile Corp. - July 30, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or... 
Via Newsfile
Topics Cannabis
Exposures Cannabis
Entheon Biomedical Further Strengthens Advisory Board with Appointment of Dr. Andy Greenshaw
Vancouver, British Columbia--(Newsfile Corp. - July 28, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or... 
Via Newsfile
How To Invest In "Magic Mushrooms" (Psychedelics)
A look at psychedelics as stock market investment opportunities and identifying alternative strategies on how to invest. 
Via Talk Markets
Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies
This article was made possible thanks to invaluable research by Michael Haichin and Josh Hardman from Ps... 
Via Benzinga
Entheon Biomedical Announces Medical Advisor, Dr. Dinesh Bhayana
Vancouver, British Columbia--(Newsfile Corp. - June 30, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or... 
Via Newsfile
Entheon Subsidiary, HaluGen Life Sciences, Partners with Maya Health to Drive Psychedelics Genetic Test Kit Awareness
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or... 
Via Newsfile
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.